-37.6%
PDD vs MRNA
+455.8%
-493.4%
-46.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | +0.7% | -1.7% | -1.0% |
| 7D | -4.6% | -8.2% | +3.6% | -4.5% |
| 30D | -14.0% | +125.6% | -139.5% | -17.1% |
| 3M | -4.9% | +197.1% | -201.9% | -9.3% |
| 6M | -25.8% | +148.5% | -174.3% | -28.8% |
| YTD | -31.4% | +363.3% | -394.6% | -36.0% |
| 1Y | -37.6% | +462.0% | -499.6% | -42.6% |
| All | -37.6% | +455.8% | -493.4% | -42.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling